Marketing-authorisation holder
Hikma Farmaceutica (Portugal) S.A.
223 medicines in 4 countries, as authorisation holder, manufacturer and marketer.
Loading your page…
Loading your page…
Marketing-authorisation holder
223 medicines in 4 countries, as authorisation holder, manufacturer and marketer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 223
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ACICLOVIR HIKMAPolvere per soluzione per infusione endovenosa | Aciclovir | Italy | Authorised | |
| Aciclovir Hikma 250 mg poeder voor oplossing voor infusiePoeder voor oplossing voor infusie | Aciclovir | Netherlands | Authorised | 2022 |
| ACICLOVIR HIKMA 250 MG POLVO PARA SOLUCION PARA PERFUSION EFG250 mg · Polvo para solución para perfusión | Aciclovir | Spain | Marketed | 2018 |
| Aciclovir Hikma 500 mg poeder voor oplossing voor infusiePoeder voor oplossing voor infusie | Aciclovir | Netherlands | Authorised | 2022 |
| ACIDO ZOLEDRONICO HIKMAConcentrato per soluzione per infusione | Zoledronic acid | Italy | Authorised | |
| ADENOSINA HIKMASoluzione iniettabile | Adenosine | Italy | Authorised | |
| ADENOSINA HIKMA 6 MG/2ML SOLUCION INYECTABLE EFG3 mg/ml · Solución inyectable | Adenosine | Spain | Marketed | 2021 |
| Adenosine Hikma 6 mg/2 ml, oplossing voor injectieOplossing voor injectie | Adenosine | Netherlands | Authorised | 2021 |
| ALOPERIDOLO HIKMASoluzione iniettabile a rilascio prolungato | Haloperidol | Italy | Authorised | |
| AMFOTERICINA B LIPOSOMAL HIKMA 50 MG POLVO PARA CONCENTRADO PARA DISPERSION PARA PERFUSION50 mg · Polvo para dispersión para perfusión | Amphotericin b | Spain | Authorised | 2026 |
| Amiodaron HCl Hikma, 50 mg/ml oplossing voor injectieOplossing voor injectie | Amiodarone | Netherlands | Authorised | 2007 |
| AMIODARONE HIKMASoluzione iniettabile | Amiodarone | Italy | Authorised | |
| ANIDULAFUNGINA HIKMA 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION EFG100 mg · Polvo para concentrado para solución para perfusión | Anidulafungin | Spain | Authorised | 2026 |
| Anidulafungine Hikma 100 mg poeder voor concentraat voor oplossing voor infusiePoeder voor concentraat voor oplossing voor infusie | Anidulafungin | Netherlands | Authorised | 2026 |
| AZACITIDINA HIKMAPolvere per sospensione iniettabile | Azacitidine | Italy | Authorised | |
| AZACITIDINA HIKMA 25 MG/ML POLVO PARA SUSPENSION INYECTABLE EFG25 mg/ml · Polvo para suspensión inyectable | Azacitidine | Spain | Marketed | 2022 |
| Azacitidine Hikma 25 mg/ml poeder voor suspensie voor injectiePoeder voor suspensie voor injectie | Azacitidine | Netherlands | Authorised | 2022 |
| BENDAMUSTINA HIKMAPolvere per concentrato per soluzione per infusione | Bendamustine | Italy | Authorised | |
| BENDAMUSTINA HIKMA 2,5 MG/ML POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION EFG2,614 mg · Polvo para concentrado para solución para perfusión | Bendamustine | Spain | Marketed | 2019 |
| BIVALIRUDINA HIKMAPolvere per concentrato per soluzione iniettabile/infusione | Bivalirudin | Italy | Authorised | |
| BIVALIRUDINA HIKMA 250 MG POLVO PARA CONCENTRADO PARA SOLUCIÓN INYECTABLE O PERFUSIÓN EFG250 mg · Polvo para concentrado para solución inyectable y para perfusión | Bivalirudin | Spain | Authorised | 2025 |
| Bivalirudine Hikma 250 mg poeder voor concentraat voor oplossing voor injectie/infusiePoeder voor concentraat voor oplossing voor injectie / infusie | Bivalirudin | Netherlands | Authorised | 2020 |
| BLEOPRIMPolvere per soluzione iniettabile | Bleomycin | Italy | Authorised | |
| Brietal Hikma, poeder voor injectievloeistof 500 mgPoeder voor oplossing voor injectie | Methohexital | Netherlands | Authorised | 1990 |
| Carboplatine Hikma 10 mg/ml concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Carboplatin | Netherlands | Authorised | 2024 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Netherlands | 89 | 89 | 0 | CompaniesAll medicines |
| Spain | 74 | 73 | 1 | CompaniesAll medicines |
| Italy | 59 | 59 | 0 | CompaniesAll medicines |
| European Union (EMA) | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of Brazil, Singapore, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.